by John.norman | Nov 23, 2022 | News
Optibrium appoints Ian Smith as Chief Technology Officer New role will lead technology development as the Company continues to scale team and global business operations. The appointment of former Merck, Sharp and Dohme (MSD) Director of R&D Analytics... by Michelle Harrison | Nov 2, 2022 | News
Optibrium and Lhasa Limited advance predictive modelling for drug-metabolising enzymes Optibrium and Lhasa Limited publish joint peer-reviewed research in the Journal of Medicinal Chemistry, expanding predictive modelling beyond human Cytochrome P450. Study... by Michelle Harrison | Oct 18, 2022 | News
Optibrium expands operations in North America for AI and computational drug discovery technologies Establishment of Optibrium Inc. bolsters ongoing strategic Company growth and strenghtens direct US customer support. Dr Tamsin Mansley promoted to President of... by John.norman | Oct 17, 2022 | News
J. Med. Chem, publish; Predicting Regioselectivity of AO, CYP, FMO and UGT Metabolism Using Quantum Mechanical Simulations and Machine Learning. Mario Öeren,† Peter J. Walton, †, ‡ James Suri, †, § David J. Ponting, ^ Peter A. Hunt, † Matthew D. Segall † †... by Michelle Harrison | Oct 3, 2022 | News
Optibrium strengthens global AI drug discovery software operations with three key appointments Michelle Harrison appointed as Head of Strategic Marketing; Chris Khoury and Imran Ghauri join to boost Optibrium’s business development team. UK and US-based... by John.norman | Jun 20, 2022 | News
Optibrium receives further investment from Kester Capital Second round of funding from existing investors will further drive company expansion and commercial growth of its AI-enabled drug discovery technology. CAMBRIDGE, UK, 21 June 2022 – Optibrium™, a developer of...
Recent Comments